Abstract
肺鳞状细胞癌(squamous-cell lung cancer, SqCLC)是非小细胞肺癌中一类独特的病理类型,患者多为高龄、发病隐匿、发现时常属晚期、常伴有心肺合并症、缺乏有效的靶向治疗药物等因素,相对于非鳞非小细胞肺癌,SqCLC的治疗面临着更大的挑战。近年针对肺癌的分子靶向药物迅速发展,我们发现,FGFR家族(FGFR1-4)基因改变存在于约12%的SqCLC中,是SqCLC中突变频率最高的酪氨酸激酶家族基因,同时许多靶向FGFR的小分子药物都在各类肿瘤中发挥了较好的治疗效果。目前,许多FGFR抑制治疗SqCLC的临床试验也都正在进行当中,可能为SqCLC治疗提供新的策略和方向。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.